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ABSTRACT 
Sjogren’s syndrome (SS) is a chronic autoimmune disease, that affects primarily salivary 
and lacrimal glands, leading to increased morbidity. Recent studies indicate that loss of salivary 
gland function is associated with defective cell polarity, lymphocytic infiltration and fibrosis. Our 
previous studies showed that deregulation of E-cadherin-mediated adhesion was associated with 
nuclear localization of YAP and suggested that the latter may be a key event in SS. In this study, 
our goal was to align altered morphological features in SS with cell polarity regulators. 
Specifically, we focused on the Par complex, known to play an important role in epithelial polarity, 
as well as components of tight junctions (TJs), ZO-1 and JAM-1, and compared them to changes 
in their expression and localization with markers of fibrosis, vimentin and a-smooth muscle actin 
(a-SMA). Using immunofluorescence staining and confocal microscopy we examined expression 
levels of YAP, Par3, ZO-1, JAM-1, vimentin, and a-SMA, and correlated them with a ductal 
differentiation marker K7 and a marker for lymphocytic infiltration, CD45+.  Our results showed 
reduced levels of Par3, ZO-1 and JAM-1, in tissues from SS patients that were associated with 
increased nuclear localization of YAP. Collectively, these studies suggest that cell polarity cues 
are critical for normal function of salivary glands and that their deregulation is likely to be the 
underlying basis of at least a subset of SS patients. These findings will further contribute to a better 
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understanding of the molecular basis of SS and will serve in improved diagnosis and future 
therapeutic intervention. 
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INTRODUCTION 
Sjogren’s syndrome (SS) is a chronic debilitating autoimmune disease mainly affecting the 
salivary and lacrimal glands and is associated with a high degree of morbidity [1]. SS is the third 
most common autoimmune disorder behind Rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) [2]. SS has been reported all over the world with some areas reporting 
prevalence as high as 3% of the population. Differences in prevalence due to race and ethnicity are 
unknown and nine out of 10 cases are reported to be females [3]. Average age of onset is between 
ages 40 and 60, although up to half of all cases may be left undiagnosed or unreported [4,5]. 
Diagnosis of SS is often delayed and complicated since the patient usually develops many non-
specific symptoms such as fatigue, joint pain, muscle pain, making them approach different 
specialists. Most of these symptoms manifest after the age of 40 making patient conclude and 
ignore them as age related. Certain medications can also lead to symptoms that mimic SS. [6] 
SS affected salivary glands show high lymphocytic infiltration, production of specific 
autoantibodies, faulty localization of proteins, dilation of ducts, acinar cell atrophy leading to 
diminished secretory capacity of acinar cells [1]. Decreased salivation leads to dryness of mouth 
(xerostomia) which in turn increases the susceptibility to caries. Decreased lacrimation leads to 
dryness of eyes (xeropthalmia) causing inflammation of cornea and conjunctiva 
(keratoconjunctivitis sicca). [1] There is no definitive treatment available for SS at this time and 
all current treatments aim at symptomatic relief. 
Molecular mechanisms driving Sjogren’s pathology remain unclear. Until recently, the 
prevailing dogma in the field has been that lymphocytic infiltration led to dysfunction and hypo-
salivation of salivary glands. However, increasing evidences suggest that impaired epithelial 
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secretion develops independent of lymphocytic infiltration, suggesting that signals emanating from 
the epithelium contribute to the etiology of SS [6]. Recent studies, including our own [7, 21], have 
also shown that the structural integrity of the epithelium of SS patients is lost, and that these defects 
are associated with aberrant apical-basal polarity [8,9]. Epithelial cells establish distinct apical-
basal asymmetry, which is controlled by protein complexes that organize adherens junctions, 
barrier forming tight junctions, and unique apical and basal-lateral domains directing secretion 
[10]. Cell polarity-regulating proteins have important roles in epithelial homeostasis, and loss of 
polarity organization is associated with defective exocrine secretion and immune responses [14, 
10-13]. Therefore, while aberrant immune cell activity is a central feature of SS, the loss of 
epithelial polarity-regulated signals is likely to be one of the underlying factors leading to SS. Cell 
polarity proteins play essential roles in controlling intracellular signals, most notably regulation of 
the Hippo pathway, that regulates tissue development, regeneration and homeostasis [15]. Irregular 
polarity can arise from environmental toxins, viral infection, physical damage, and unbalanced 
hormone levels. Hence, it may be an early event that triggers disease states, including SS.  
Our investigation into molecular signals that contribute and respond to epithelial defects in 
SS has identified dysregulation of the Hippo pathway effector YAP. YAP is an important 
transcriptional regulator. The best described roles for YAP have been in the context of cancer 
where dysregulated nuclear YAP is often associated with tumorigenesis [16]. However, increasing 
evidences indicate that aberrant nuclear YAP activity contributes to a wide-range of diseases [16] 
including fibrosis, immune dysfunction, as well as heart, lung and skin disorders. Based on 
published studies and our preliminary data, we hypothesize that SS is one of such diseases driven 
by abnormal YAP activity [17]. Notably, increased nuclear YAP activity resulting from disruption 
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of Hippo pathway activity drives lymphocytic infiltration, based on studies in the pancreas 
epithelium [18, 19]. The pancreas shares similar anatomical structures and physiological functions 
with the salivary gland epithelium, which prompted us to test the relationship of YAP and SS. 
Based on our observations we hypothesize that loss of cell polarity leads to unrestricted nuclear 
YAP activity in salivary gland epithelium, thereby driving a regenerative epithelial state along 
with changes in the stromal microenvironment that trigger aberrant immune activity. Consistent 
with our hypothesis, increased nuclear YAP resulting from disruption of Hippo pathway activity 
is known to drive lymphocytic infiltration [18-20]. Our experiments will provide new insight that 
will hopefully pave ways for the development of novel diagnostics and therapeutic interventions 
for SS.  
Cell polarity is a feature of epithelial cells, showing distinct 'apical', 'lateral' and 'basal' 
plasma membrane domains and polarity proteins play a role in generating and maintaining this 
polarity. This polarity regulating proteins include Par3 (Bazooka in Drosophila), Par6/aPKC, 
Crumbs/PALS1 (Stardust in Drosophila)/PATJ, Dlg/Scrib/Lgl, MARK1/2 (Par1), 14-3-3 (Par5), 
and LKB1 (Par4) [61]. Par3 and Par6 function together with aPKC to control initial stages of 
polarization in C. elegans and Drosophila embryos [22], Drosophila neuroblast asymmetric cell 
division [23], and establishment of epithelial cell apical–basal polarity and the axon–dendrite 
polarity of neurons [24-27]. In addition, cell polarity protein, zona occludens-1 (ZO-1), functions 
in the assembly of tight junctions (TJs) apically from E-cadherin-mediated adherens junctions 
(AJs). TJs are responsible for the sealing of epithelia, in part, by establishing a link between the 
transmembrane protein occludin and the actin cytoskeleton [28].  ZO-1 is expressed in acinar, 
ductal and endothelial cells [29]. Tight junctions (TJs) [30] and AJs [31] are 2 of the 4 major 
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components of intercellular junctional complex in epithelial cellular sheets. Salivary gland AJs 
consist of cadherin family, which are important in salivary gland development, tissue organization, 
and cell differentiation [32]. E-cadherin and β-catenin form stable cell-cell contacts during 
cytodifferentiation and establish and maintain salivary cell polarity [24]. TJs further contribute to 
cell polarity in epithelial cells [25,26], and localization of ZO-1 is associated with formation of the 
AJs [33, 34].  
Junctional adhesion molecule 1 (JAM-1) represents another component localized at TJs 
[35].  JAM plays a role in the organization of TJs by interacting with ZO-1, cingulin and occludin 
[36], all involved in the regulation of junctional integrity and permeability [37]. Any defects 
affecting ZO-1 and JAM-1 can negatively contribute to altered cell polarity leading to decreased 
production of saliva by salivary gland causing xerostomia. 
In SS, lymphocytic infiltration causes fibrosis and hypo-salivation. Here, in the early phase 
of granulation tissue formation fibroblasts differentiate into a-smooth muscle actin (a-SMA) 
containing myofibroblasts [38]. Myofibroblasts act as a contractile apparatus similar to that of 
smooth muscle [38] and this contractile force is essential for efficient closure and healing of the 
wound [39,40]. When the wound closes, myofibroblasts are cleared through apoptosis [41]; on the 
other hand, their persistence is associated with development of scarring and fibrosis [42]. In 
addition, vimentin is expressed in fibroblasts, myofibroblasts, endothelial cells, activated 
lymphocytes and nerve cells. Vimentin is a type III intermediate filament protein that is a major 
cytoskeletal component of mesenchymal cells. Because of this, vimentin is often used as a marker 
of mesenchymal derived cells. Vimentin plays a role in the changes in shape, loss of adhesion, and 
increased motility that occur during the epithelial to mesenchymal transitions (EMT) [43]. Anti-
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vimentin antibodies are found after heart and kidney transplantation [44-47] and are also associated 
with autoimmune diseases such as rheumatoid arthritis [48] and systemic lupus erythematosus 
[49]. Vimentin is required for wound repair and remodeling in alveolar epithelial cells, and it is 
upregulated after alveolar injury [50]. In our study, we hypothesize that upregulation of vimentin 
may be due to the defect or injury to salivary gland epithelial cells. Vimentin intermediate 
filaments are active in lymphocyte adhesion and transmigration [51]. Higher expression level of 
vimentin is also correlated with increased presence of activated lymphocytes. 
Loss of cell polarity leads to lymphocytic infiltration [14, 10-13], which is a hallmark of 
SS. CD45+ is expressed in all leukocytes and is also known as lymphocyte common antigen. 
Expression of CD45+ is essential for the activation of T-cells [52]. Considerable evidence 
indicates that the expression of molecules from the CD45+ family [51, 53, 54] on T cells, is 
essential for efficient activation of these cells via the T Cell receptor (TCR) [52].  CD45+ is used 
as a marker for lymphocytic infiltration. SS affected salivary glands show high lymphocytic 
infiltration with aberrant duct formation [1], as demonstrated by aberrant expression of keratin-7 
(K7), a type II intermediate filament and a ductal marker [56]. Keratins are expressed in all types 
of epithelial cells (simple, stratified, keratinized and cornified) [55, 56], and they are found in the 
simple epithelia lining the cavities of the internal organs and in the gland ducts and blood vessels 
[55].  
The goal of our studies was to test the association between epithelial polarity and YAP and 
correlate them with the pathophysiology of SS. In addition, we aimed to elucidate molecular details 
of how epithelial dysfunction contributes to SS. We focused on the Par complex known to play an 
important role in epithelial polarity, as well as components of TJs, ZO-1 and JAM-1, and compared 
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their changes in expression and localization with markers of fibrosis that accompany salivary gland 
dysfunction, vimentin and a-SMA. Specifically, using immunofluorescence staining and confocal 
microscopy we examined expression levels and localization of YAP, Par3, ZO-1, JAM-1, 
vimentin, and a-SMA, and correlated them with a ductal differentiation marker K7 and 
lymphocytic infiltration marker, CD45+. 
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MATERIALS AND METHODS 
Minor human salivary glands 
Formalin fixed, paraffin embedded labial salivary glands from the lower lip of patients 
diagnosed with SS, with non-SS glands used as negative controls (six specimens). Tissues were 
collected with a written consent from three different biobanks in Oslo, Norway. The Norwegian 
Committee of Ethics approved the use of the biopsies in the study. To assure proper diagnosis, an 
oral pathologist re-evaluated all biopsies blindly using American-European Consensus Criteria 
(AECC) to determine the focus score (the number of focal mononuclear cell infiltrates with ≥50 
mononuclear cells per 4 mm2). Minor salivary glands evaluated for SS, and those not fulfilling 
AECC criteria served as controls.  Patients with SSA or SSB autoantibodies, or patients diagnosed 
with secondary SS, were excluded as controls. For each marker analyzed by immunostaining, a 
minimum of six biopsies from SS compatible patients and six non-compatible controls were used.   
Antibodies 
Antibodies to K-7, produced in mouse, YAP, produced in rabbit, JAM-1, produced in rat, 
and CD-45, produced in rabbit, were purchased from abcam, MA, USA. Antibodies to vimentin, 
produced in mouse and a-SMA, produced in mouse were purchased from Sigma-Aldrich, St. 
Louis, MO. Antibodies to par-3, produced in rabbit, was purchased from EMD Millipore, MA, 
USA. Antibody to ZO-1, produced in rabbit, was purchased from ThermoFisher scientific, MA, 
USA. 
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Immunofluorescence analysis 
                         Formalin fixed paraffin-embedded human labial salivary glands biopsies were cut 
into 4-6µm sections using a Leica serial Microtome (Leica Instruments, Solms, Germany) and 
placed on SuperFrost Plus microscopes slides (Thermo Scientific, MA, USA). Before staining, 
each slide was rinsed in distilled water prior to heat induced deparaffinization and antigen retrieval 
in a microwave using 4.7ml of antigen unmasking solution (H-3300 from Vector Laboratories, 
Burlingame, CA) in 500ml of MilliQ water.  Leave slides on bench to cool to room temperature. 
Rinse slides in PBS once for 3 minutes. Dry around samples and mark circle around sample with 
pap pen prior to 1 hour blocking in 5% goat serum (Sigma) in PBS at room temperature. Sections 
were incubated in primary antibodies diluted in PBS-T (20mM Tris, 137mM NaCl, 0.1% Tween 
20, pH 7.6) with 10% BSA overnight at 4-degree C. The slides were washed in PBS-T four times 
for 3 minutes each. Secondary antibodies are spin down for 10 minutes at 15000 rpm. Sections are 
then incubated with secondary antibodies diluted in PBS-T for one hour at room temperature. 
Slides are washed in PBS four times for 5 minutes each and then counterstained for nuclei with 
DAPI (Invitrogen) diluted at 1:1000 in PBS-T at room temperature for 2 minutes. Slides are then 
washed once for 3 minutes in PBS-T and spun down at 700rpm for 1 minute to dry. Add one drop 
of ProLong (Invitrogen) antifade reagent to the side and cover with Microscope Cover Glass 
(Fisher Scientific, MA, USA). Leave it to dry overnight at room temperature. For negative 
controls, the primary antibodies were omitted. The immuno-stained slides were then analyzed 
using a Zeiss LSM 510 confocal microscope. 
 
 
	   9	  
RESULTS 
Hippo signaling pathway is required for salivary gland development and its dysregulation 
is associated with Sjogren's-like disease [7, 21]. YAP is one of the effectors of Hippo signaling 
pathway. Junctional localization of YAP has been shown to be associated with the presence of Par 
proteins in the apical regions of polarized cells. To determine whether salivary cell dysfunction in 
SS was associated with mislocalization of YAP, we examined its expression and localization using 
immunofluorescence staining coupled with confocal microscopy. As shown in Fig.1, more nuclear 
YAP was expressed in human salivary gland acinar cells of patients with Sjogren’s disease 
compared to non-SS specimen (Fig 1a). Highly immune infiltrated area showed more 
nuclear/cytoplasmic YAP (Fig. 1b) compared to low immune infiltrated area (Fig. 1c). Fig 1c 
shows graphic representation of YAP in SS and non-SS specimens. Non-SS specimens showed 
64% of junctional/basal YAP and 36% of nuclear/cytoplasmic YAP. SS specimens with high 
immune infiltration showed 77% of nuclear/cytoplasmic YAP and 23% junctional/basal YAP. SS 
specimens with low immune infiltration showed 73% nuclear/cytoplasmic YAP and 27% 
junctional/basal YAP.  
Epithelial cell polarity is mainly controlled by polarity proteins, including Par3 [61]. To 
determine if increased nuclear YAP localization was associated with altered Par proteins 
expression and localization, we examined Par 3 in SS tissues, while non-SS samples displayed 
more robust Par 3 at apical junctions (Fig2a). Further, SS specimens with high immune infiltration 
(Fig. 2c) exhibited less Par3 expression compared to SS specimens with low immune infiltration 
(Fig. 2b). Our results show that in SS, there is an increased level of nuclear YAP, which in turn 
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may affect expression of target genes leading to defective organ development. Additionally, 
decreased expression of Par3 in SS specimen is associated with disrupted cell polarity.  
We also examined expression of other polarity proteins, ZO-1 and JAM-1, in SS. Using 
immunofluorescence staining coupled with confocal microscopy, we found that compared to non-
SS, ZO-1and JAM-1 expression levels were decreased in SS. Specifically, results showed 
decreased ZO-1 expression levels in high immune infiltrated area (Fig. 3c) compared to low 
immune infiltrated area (Fig. 3b). JAM-1 expression levels were also decreased in high immune 
infiltrated area (Fig. 4c) compared to low immune infiltrate area (Fig. 4b). Other studies have 
shown that loss of cell polarity and secretory dysfunction are associated with Sjogren's syndrome 
[57]. Decreased expression levels of Par3, ZO-1 and JAM-1 are associated with disrupted cell 
polarity, which in turn might affect the excretory properties of ductal cells causing decreased 
salivary production, which is a hallmark of Sjogren’s disease. 
Given that SS is frequently associated with fibrotic phenotypes, we next assessed the 
expression and localization of two key markers of this condition, vimentin and aSMA. Vimentin 
is a type III intermediate filament protein that is expressed in mesenchymal cells and is used as a 
marker for myofibroblast formation.  In addition, α-SMA is used as a marker of myofibroblast 
formation [38]. We examined the expression and localization of vimentin and a-SMA using 
immunofluorescence staining coupled with confocal microscopy. Both vimentin and a-SMA were 
upregulated in salivary gland specimens from SS patients compared to non-SS (Fig.5 and Fig.6). 
Tissues from SS patients (Fig. 5c and Fig. 6c) showed more robust vimentin and a-SMA 
expression compared to non-SS (Fig.5b and Fig.5c).  
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In SS, salivary gland dysfunction is associated with lymphocytic infiltration, with CD45+ 
serving as a marker for T-cell inflamed glands. We examined the expression and localization of 
CD45+ using immunofluorescence coupled with confocal microscopy. CD45+ was upregulated in 
salivary gland specimens from SS patients compared to non-SS (Fig7a). High immune infiltrated 
area (Fig.7c) showed more expression levels of CD45+ compared to low immune infiltrated area 
(Fig.7b). 
From the above data, we conclude that loss of cell polarity and dysregulated nuclear 
accumulation of YAP can lead to defective duct formation, which can affect the secretory functions 
of salivary gland. Given that K7 is a ductal marker [56], we examined its expression and 
localization by immunofluorescence staining. Confocal images of SS tissues revealed disorganized 
ductal structures as marked by K7 (Fig.8b) compared to non-SS (Fig.8a). 
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DISCUSSION 
Using immunofluorescent staining and confocal microscopy we examined expression 
levels of YAP, Par3, ZO-1, JAM-1, vimentin, α-smooth muscle actin, CD-45, and K-7 in both 
non-Sjogren’s and Sjogren’s syndrome patients to better understand the molecular mechanism 
involved in Sjogren’s syndrome. 
Our studies show that there is an increase in nuclear and cytoplasmic YAP expression 
compared to non-SS patients, where YAP clearly localized to basal and junctional regions.  This 
increase may be due to deregulation of E-cadherin-mediated control of cellular localization of 
YAP. This result is consistent with the function of LATS1 and LATS2 kinases, which 
phosphorylate YAP to induce binding to 14-3-3 proteins and E-cadherin-associated AJs to restrict 
nuclear accumulation of YAP [58, 59]. Other studies have shown that salivary glands from 
Sjogren’s patients display AJ defects with disrupted E-cadherin junctional localization [2, 60], and 
this can also explain the disrupted expression pattern of YAP in SS patient samples.  
  Epithelial cell polarity is controlled by polarity proteins including, Par3 [61]. Growing 
evidences shows that Par3 and Par6 function together with aPKC to regulate initial stages of 
polarization in C. elegans and Drosophila embryos [22], and in the establishments of mammalian 
epithelial cell apical–basal polarity [24-27]. Our data show that Par-3 expression levels were 
decreased in SS patients compared to non-SS patients. The decreased expression levels of Par3 in 
SS patients may be due to the loss of polarity in acinar cells of patients with SS. These data further 
confirm that apical–basal polarity is disrupted in the salivary glands of SS patients. 
In addition to AJs, TJs [30] are also major components of intercellular junctional 
complexes in epithelial cellular sheets. TJ transmembrane proteins are anchored to the actin 
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cytoskeleton by ZO proteins [27, 28]. ZO-1 is known to be expressed in acinar, ductal and 
endothelial cells [29]. Both ZO-1 and TJs contribute to cell polarity in epithelial cells [25,26] and 
are important for salivary gland function. In our study, ZO-1 expression levels were decreased in 
patients with SS, which further indicates loss of cell polarity and disrupted TJs, which in turn 
causes dysfunction of salivary glands in SS patients. In addition, levels of JAM-1 were reduced in 
SS patients, further confirming that the cell polarity complexes involving ZO-1 and JAM-1 are 
diminished in SS patients.    This was associated with impaired K7 distribution, indicating defects 
in ductal structures in SS patients.   
In SS, high lymphocytic infiltration is frequently associated with fibrosis, caused by a-
SMA-containing myofibroblasts that act as a contractile apparatus similar to that of the smooth 
muscle [38]. Persistence of myofibroblasts is associated with scarring and fibrosis [42]. Our study 
showed upregulation of α-SMA in SS patients that may be due to damage of salivary glands 
leading to increased differentiation of fibroblasts into myofibroblasts for tissue healing. In 
addition, our studies showed upregulation of vimentin in SS tissues, which may be due to the 
defect or injury to salivary gland epithelial cells. Since the salivary gland has self-renewal function 
and in SS patients, and the salivary gland is under constant attack by immune cells, it is likely that 
vimentin is upregulated to adapt to the repair needs of the tissue. It has been shown that vimentin 
intermediate filaments are active in lymphocyte adhesion and transmigration [51], suggesting that 
higher expression levels of vimentin are correlated with increased presence of activated 
lymphocytes. Indeed, our studies showed that CD45+ was upregulated in salivary gland specimens 
from SS patients which correlated with increased vimentin expression.  
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CONCLUSION 
We conclude that defective cell polarity may play a role in the pathobiology of SS by 
inducing infiltration of salivary tissues by lymphocytes. We show that cell polarity defects include 
reduced organization of AJs and TJs, concomitant with mislocalization of YAP to the nucleus. 
Thus, enhancing AJs/TJs and the Hippo pathway function may interfere with SS development and 
progression.  
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Figure 1 
Figure 1a                                                         Figure 1b 
 
 
 
 
 
 
 
 
 
                              
 
 
 
 
 
                          Non-SS                                                             SS – low immune infiltration 
 
                                             
                                          Figure 1c 
 
 
 
 
 
 
 
 
 
 
                                                   
 
 
 
 
 
                                                   SS – high immune infiltration 
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Figure 1d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(P < 0.05) 
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Figure 1a: Immunofluorescence localization of YAP in non-SS. More junctional and basal YAP 
expression is noted with confocal microscopy. Size bar: 20 µm. 
Figure 1b: SS with low immune infiltration. Localization of YAP is more in the 
nuclear/cytoplasmic area. This is studied with help of immunofluorescence staining and confocal 
microscopy. Size bar: 20 µm. 
Figure 1c: SS with high immune infiltration. Size bar: 20 µm. Immunofluorescence staining and 
confocal microscopy show more YAP localization in the nuclear/cytoplasmic area compared to 
low immune infiltration. 
Figure 1d: Shows graphical representation of junctional/basal YAP expression and 
nuclear/cytoplasmic YAP expression in non-SS and SS patients. SS with high immune infiltration 
and low immune infiltration areas show more nuclear YAP compared to healthy control with a p 
value of 3.4047E-09 (<0.05) and 7.5153E-07 (<0.05) respectively. 
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Figure 2 (PAR-3) 
 
 Figure 2a                                                                     Figure 2b 
 
                   Non-SS                                                                           SS – low immune infiltration                                 
                                       
 
                                      Figure 2c 
 
 
 
 
 
 
 
 
 
 
 
                                                       
 
 
 
 
 
 
 
                                                   SS – high immune infiltration 
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Figure 2: Immunofluorescence staining coupled with confocal microscopy show high PAR-3 
expression in non-SS (Figure 2a) compared to SS with low immune infiltration (Figure 2b) and 
SS with high immune infiltration (Figure 2c). Size bar: 20 µm. 
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Figure 3 (ZO-1) 
 
Figure 3a Figure 3b  
 
                             Non-SS                                                          SS – low immune infiltration 
  
                           
                                        Figure 3c 
                              
 
 
 
 
 
 
 
 
 
 
                                                         
 
 
 
 
 
                                                      SS – high immune infiltration 
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Figure 3: Immunofluorescence staining coupled with confocal microscopy show high ZO-1 
expression in non-SS (Figure 3a). SS with low immune infiltration (Figure 3b) and SS with high 
immune infiltration (Figure 3c) showed decreased ZO-1 expression levels. Size bar: 20 µm. 
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Figure 4 (JAM-1) 
 
Figure 4a                                      Figure 4b 
 
                              Non-SS                                                         SS- low immune infiltration 
 
                          
                       
                                            Figure 4c 
 
 
 
 
 
 
 
 
 
 
                                          
 
 
 
 
 
                                      
                                                             SS-high immune infiltration 
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Figure 4: Immunofluorescence staining coupled with confocal microscopy show high JAM-1 
expression in non-SS (Figure 4a). SS with low immune infiltration (Figure 4b) and SS with high 
immune infiltration (Figure 4c) showed decreased JAM-1 expression levels. Size bar: 20 µm. 
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Figure 5 (Vimentin) 
 
Figure 5a Figure 5b  
 
                            Control                                                                         Non-SS 
 
            Figure 5c 
 
 
 
 
 
 
 
 
 
                                              
 
 
 
 
 
                                                    
                                                      SS- with immune infiltration 
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Figure 5: Immunofluorescence staining coupled with confocal microscopy show high Vimentin 
expression in SS (Figure 5c) compared to non-SS patients (Figure 5b) Size bar: 20 µm. 
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Figure 6 (a-SMA) 
 
Figure 6a                                                                 Figure 6b  
 
 
 
 
 
 
 
 
 
 
                            
 
 
 
 
 
                          Control                                                                   Non-SS                        
 
 
 Figure 6c 
 
 
 
 
 
 
 
 
                
                                                 
 
 
 
 
                        
                                                SS-with immune infiltration 
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Figure 6: Immunofluorescence staining coupled with confocal microscopy show high a-SMA 
expression in SS (Figure 6c) compared to non-SS patients (Figure 6b) Size bar: 20 µm. 
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Figure 7(CD45+) 
 
Figure 7a Figure 7b  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          Non-SS                                                              SS – low immune infiltrate 
 
 
 
                                          Figure 7c 
 
 
 
 
 
 
 
 
 
                                           
                                                           
 
 
 
 
 
                                                          SS – high immune infiltrate 
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Figure 7: Immunofluorescence staining coupled with confocal microscopy show high CD-45 
expression in both SS with low-immune infiltration (Figure 7b) and high-immune infiltration 
(Figure 7c) compared to non-SS patients (Figure 7a) Size bar: 20 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   30	  
Figure 8 (K-7) 
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Figure 8: Immunofluorescence staining coupled with confocal microscopy show K7 expression 
in non-SS salivary gland ducts. Well organized K7 pattern interpreted as well-organized ducts in 
these glands (Figure 8a). Disorganized K7 pattern in SS salivary glands shows aberrant duct 
formation (Figure 8b). Size bar: 20 µm. 
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